Dr. Jennings regulatory experience encompasses drug development across multiple therapeutic realms, including diabetes, cardiovascular disease, obesity, viral infections and hematology. Amy is currently SVP, Head of Regulatory Affairs at Casebia Therapeutics, a company looking to harness the power of gene editing to transform the lives of patients and families affected by a wide array of genetic diseases. Prior to Casebia, Amy was the SVP, Head of Regulatory at Achillion Pharmaceuticals, where she was responsible for global regulatory strategy, regulatory operations, quality assurance and medical writing. During her time at Achillion, Dr. Jennings led successful IND submissions for two rare disease indications for which phase 2 patient trials are ongoing. Earlier, Dr. Jennings served as Sanofi’s associate vice president for global regulatory affairs in the company’s North American diabetes program. At Sanofi she led a US and global regulatory affairs team and was also responsible for labeling and advertising/promotions. Before Sanofi, Dr. Jennings held positions of increasing responsibility at Bristol-Myers Squibb, including leadership of US regulatory affairs for its cardiovascular/metabolic programs. She was ultimately group director in global regulatory affairs for special products. During her tenure at BMS, Dr. Jennings headed regulatory efforts that led to the approval of two new diabetes drugs. Amy was a post-doctoral fellow at the Harvard-affiliated Joslin Diabetes Center. She received her Ph.D. in Biochemistry from The Ohio State University and her Bachelor of Science in Chemistry from the University of Wisconsin-Madison.